极低 LDL-C(<30 mg/dL)的安全性与前沿进展
综述探讨将 LDL-C 降至极低水平(<30 mg/dL)的心血管获益与安全性。现有他汀、依折麦布、PCSK9 抑制剂可实现极低 LDL-C,事件减少随 LDL-C 降低呈对数线性增加且未见明确平台。极低 LDL-C 的长期安全性(如新发糖尿病、出血性卒中)尚存争议,特定高危人群可能获益。
要点
- LDL-C 降低与心血管事件减少呈对数线性关系,极低水平未见明确平台。
- 他汀、依折麦布、PCSK9 抑制剂可使越来越多患者达到极低 LDL-C(<30 mg/dL)。
- 极低 LDL-C 的长期安全性(新发糖尿病、出血性卒中)尚存争议,需长期数据。
核心结论
- 极低 LDL-C(<30 mg/dL)可能带来心血管获益且短期安全性可接受,特定高危人群或可获益。
- 极低 LDL-C 的长期安全性争议未决,需进一步研究比较其与现行推荐目标的疗效与安全性。
研究设计与样本
- 综述:分析以极低 LDL-C 为特征的家族性情况,并汇总患者达到极低 LDL-C 的降脂药物试验。
主要发现
- 心血管事件减少随 LDL-C 降低呈对数线性增加,即使达到极低 LDL-C 也未出现明确平台。
- 极低 LDL-C 是否与显著临床不良反应(如新发糖尿病或出血性卒中)相关仍存争议,需长期数据。
临床怎么用
- 在特定高危人群中,可考虑将 LDL-C 降至极低水平(<30 mg/dL)以获取心血管获益。
- 需权衡极低 LDL-C 的潜在获益与短期安全性,长期安全性尚待明确。
局限性
- 极低 LDL-C 的长期安全性数据不足,不良反应争议未决。
- 缺乏非降 LDL-C 干预与极低 LDL-C 策略的净临床获益比较。
- 缺乏极低 LDL-C 与现行推荐目标的疗效和安全性直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-density lipoprotein cholesterol (LDL-C) is a proven causative factor for developing atherosclerotic cardiovascular disease. Individuals with genetic conditions associated with lifelong very low LDL-C levels can be healthy. We now possess the pharmacological armamentarium (statins, ezetimibe, PCSK9 inhibitors) to reduce LDL-C to an unprecedented extent. Increasing numbers of patients are expected to achieve very low (<30 mg/dL) LDL-C. Cardiovascular event reduction increases log linearly in association with lowering LDL-C, without reaching any clear plateau even when very low LDL-C levels are achieved. It is still controversial whether lower LDL-C levels are associated with significant clinical adverse effects (e.g. new-onset diabetes mellitus or possibly haemorrhagic stroke) and long-term data are needed to address safety concerns. This review presents the familial conditions characterized by very low LDL-C, analyses trials with lipid-lowering agents where patients attained very low LDL-C, and summarizes the benefits and potential adverse effects associated with achieving very low LDL-C. Given the potential for cardiovascular benefit and short-term safe profile of very low LDL-C, it may be advantageous to attain such low levels in specific high-risk populations. Further studies are needed to compare the net clinical benefit of non-LDL-C-lowering interventions with very low LDL-C approaches, in addition to comparing the efficacy and safety of very low LDL-C levels vs. current recommended targets.
引用
- Karagiannis AD, Mehta A, Dhindsa DS, et al. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021. PMID: 33463677. doi:10.1093/eurheartj/ehaa1080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。